These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38700736)

  • 1. The impact of different perspectives on the cost-effectiveness of remote patient monitoring for patients with heart failure in different European countries.
    Mokri H; van Baal P; Rutten-van Mölken M
    Eur J Health Econ; 2024 May; ():. PubMed ID: 38700736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands.
    Mokri H; Clephas PRD; de Boer RA; van Baal P; Brugts JJ; Rutten-van Mölken MPMH
    Eur J Heart Fail; 2024 May; 26(5):1189-1198. PubMed ID: 38560762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries.
    Mokri H; Kvamme I; de Vries L; Versteegh M; van Baal P
    Eur J Health Econ; 2023 Jul; 24(5):701-715. PubMed ID: 35925501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
    Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
    JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
    Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
    Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation.
    Pandor A; Thokala P; Gomersall T; Baalbaki H; Stevens JW; Wang J; Wong R; Brennan A; Fitzgerald P
    Health Technol Assess; 2013 Aug; 17(32):1-207, v-vi. PubMed ID: 23927840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of remote monitoring of patients with an implantable cardiac defibrillator (REMOTE-CIED study).
    de Graaf G; Timmermans I; Meine M; Alings M; Pedersen SS; Mabo P; Zitron E; Redekop K; Versteeg H
    J Telemed Telecare; 2024 Aug; 30(7):1173-1185. PubMed ID: 36245363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the monitoring of chronic heart failure in Argentina: is the implantable pulmonary artery pressure with CardioMEMS Heart Failure System cost-effective?
    Alcaraz A; Rojas-Roque C; Prina D; González JM; Pichon-Riviere A; Augustovski F; Palacios A
    Cost Eff Resour Alloc; 2021 Jul; 19(1):40. PubMed ID: 34243782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
    Kolovos S; Bellanca L; Groyer H; Rosano GMC; Solé A; Gaultney J; Linden S
    ESC Heart Fail; 2023 Dec; 10(6):3385-3397. PubMed ID: 37670496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-time pulmonary artery pressure monitoring in heart failure patients: an updated cost-effectiveness analysis.
    Cowie MR; Thokala P; Ihara Z; Adamson PB; Angermann C
    ESC Heart Fail; 2023 Oct; 10(5):3046-3054. PubMed ID: 37591524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A telemonitoring programme in patients with heart failure in France: a cost-utility analysis.
    Caillon M; Sabatier R; Legallois D; Courouve L; Donio V; Boudevin F; de Chalus T; Hauchard K; Belin A; Milliez P
    BMC Cardiovasc Disord; 2022 Oct; 22(1):441. PubMed ID: 36217130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States.
    Sheinson D; Dang J; Shah A; Meng Y; Elsea D; Kowal S
    Adv Ther; 2021 Apr; 38(4):1811-1831. PubMed ID: 33650025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    McMurray JJV; Trueman D; Hancock E; Cowie MR; Briggs A; Taylor M; Mumby-Croft J; Woodcock F; Lacey M; Haroun R; Deschaseaux C
    Heart; 2018 Jun; 104(12):1006-1013. PubMed ID: 29269379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation and costs of remote patient monitoring for cardiovascular disease in the United States: a systematic review.
    Zhang Y; Peña MT; Fletcher LM; Lal L; Swint JM; Reneker JC
    Int J Technol Assess Health Care; 2023 Apr; 39(1):e25. PubMed ID: 37114456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
    Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
    Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a Heart Failure Telemonitoring Program Through a Microsimulation Model: Cost-Utility Analysis.
    Boodoo C; Zhang Q; Ross HJ; Alba AC; Laporte A; Seto E
    J Med Internet Res; 2020 Oct; 22(10):e18917. PubMed ID: 33021485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC
    Li X; Bilcke J; van der Velden AW; Bruyndonckx R; Coenen S; Bongard E; de Paor M; Chlabicz S; Godycki-Cwirko M; Francis N; Aabenhus R; Bucher HC; Colliers A; De Sutter A; Garcia-Sangenis A; Glinz D; Harbin NJ; Kosiek K; Lindbæk M; Lionis C; Llor C; Mikó-Pauer R; Radzeviciene Jurgute R; Seifert B; Sundvall PD; Touboul Lundgren P; Tsakountakis N; Verheij TJ; Goossens H; Butler CC; Beutels P;
    Eur J Health Econ; 2023 Aug; 24(6):909-922. PubMed ID: 36131214
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.